Clinical Trial: Triweekly Insulin Degludec a Bad Idea for TII; Stick with Daily Dose


In 2 phase 3 trials examining the concept of triweekly dosing with the long-acting insulin degludec (Tresiba, Novo Nordisk) in patients with type 2 diabetes, the recipients had inferior glucose control and an increased risk for hypoglycemia.

Read more

Posted in Drugs Glucose & Insulin Type II